POPULARITY
16 episodes with henry m
3 episodes with henry m
2 episodes with henry m
2 episodes with henry m
2 episodes with henry m
2 episodes with henry m
6 episodes with henry m
2 episodes with henry m
2 episodes with henry m
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/east-asian-studies
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/political-science
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/world-affairs
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/sociology
"The contempt and naive idealization of China are two sides of the same coin. The latter cannot be an antidote to the former." So argues Ho-Fung Hung in the conclusion of The China Question: Eight Centuries of Fantasy and Fear (Cambridge University Press, 2026). For centuries, Western scholars portrayed China either as a land of superior morality, economy, and governance or as a formidable country of pagans that posed a global threat to Western values. Idealized images of China were used to shame rulers for their incompetence, while China was demonized as an external threat to cover up domestic political failures. In the twentieth century, the geopolitics of global capitalism have facilitated more nuanced perspectives, but the diversifying of knowledge about China is far from complete. In this thought-provoking study, Ho-fung Hung finds that both Western elites and China's authoritarian regime today continue to promote many Orientalist stereotypes to advance their economic interests and political projects. He shows how big-picture historical, social, and economic changes are inextricably linked to fluctuations in the realm of ideas. Only open debate can overcome extremes of fantasy and fear. Ho-Fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department and the Paul H Nitze School of Advanced International Studies, Johns Hopkins University. Lucas Tse is Examination Fellow at All Souls College, Oxford. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/politics-and-polemics
El PP vuelve a exhibir su hipocresía: mientras paga con dinero público conciertos de Henry Méndez, un artista que desde el escenario gritó “odio a los rojos”, exige a RTVE que cese a la periodista Sarah Santaolalla por criticar su estrategia política. La derecha que presume de defender la “libertad de expresión” no duda en censurar voces críticas, mientras financia propaganda ideológica disfrazada de cultura. Otro ejemplo más del doble rasero y de quiénes son los verdaderos ofendiditos. Mas vídeos de Pandemia Digital: https://www.youtube.com/c/PandemiaDigital1 Si quieres comprar buen aceite de primera prensada, sin intermediarios y ayudar de esa forma a los agricultores con salarios justos tenemos un código de promoción para ti: https://12coop.com/cupon/pandemiadigital/ Este video puede contener temas sensibles, así como discursos de odi*, ac*so, o discr*minación. El objetivo de abordar estos temas es exclusivamente informativo y busca concienciar a la audiencia sobre estos acontecimientos, y denunciar y señalar el origen de los mismos para crear consciencia y evitar su propagación. Si consideras que el contenido puede afectarte, te recomendamos proceder con precaución o evitar su visualización. ----------------------------------------------------------------------------------------------- Únete a nuestra comunidad de YouTube https://www.youtube.com/channel/UCFOwGZY-NTnctghtlHkj8BA/join Se mecenas de Patreon https://www.patreon.com/PandemiaDigital ----------------------------------------------------------------------------------------------- Súmate a la comunidad en Twitch - En vivo de Lunes a Jueves: https://www.twitch.tv/pandemiadigital Sigue nuestro Canal de Telegram: https://t.me/PandemiaDigital Suscríbete en nuestra web: https://PandemiaDigital.net Sigue nuestras redes: Twitter: https://twitter.com/PandemiaDigitaI Facebook: https://www.facebook.com/PandemiaDigitalObservatorio Instagram: https://www.instagram.com/pandemia_digital_twitch TikTok: https://www.tiktok.com/@pandemiadigital #PandemiaDigital
Comenzamos con ´Wannabe´ de Spice Girls, de 1996, el sencillo llegó al puesto número 1 en Reino Unido, pero que ha viajado por el charco y ha llegado hasta nuestras discotecas. Volvemos a España con Estopa y su canción por la ´Raja de tu falda´ de 1999, inspirada en una historia real. Seguimos con el grupo Loco mia con la canción ´Locomia´ de 1990, que llegó a ser número 1 en los 40 principales, y que existe un documental del grupo en Netflix: ´Disco, Ibiza, Locomía´, que está protagonizado por Jaime Lorente, que hace el papel de Xavi Font. Y por último, ´El tiburón´, de Proyecto 1, de 1993, que se ha proyectado en muchos países, llegando incluso a Japón y Tailandia. Donde existe una versión de Henry Méndez de 2013 y este año es el 50 aniversario de la película ´Tiburón´, de 1975, dirigida por Steven Spielberg.
El cantant ha parlat sobre la seva vida en la música
In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.
El Guillem Solé de Buhos, l'Éric Vergés d'Els Catarres i l'Henry Méndez han estat els nous invitats del Bacstage de Flaixbac! Els tres músics ens han presentat “No és Miami”, la seva aposta per convertir-se en l'èxit d'aquest estiu, i han aprofitat per explicar-nos tots els detalls de com va sorgir la cançó.#NOÉSMIAMI #BUHOS #ELSCATARRES #HENRYMÉNDEZ00:00 a 00:30 - Intro00:30 a 02:12 - Com esteu i per què tan bronzejats?02:12 a 05:40 - Com sorgeix la col·labo? (Gerard Romero)05:40 a 06:49 - La cançó de l'estiu?06:49 a 10:20 - "Estils diferents, però a la vegada semblants" i per què Miami?10:20 a 13:20 - Cançons que no poden fallar a una playlist de l'estiu i apostes per la cançó de l'estiu 202513:20 a 16:19 - L'estrena de "NO ÉS MIAMI" i el concert de vespreig mediterrani amb Buhos i Els Catarres en joc16:19 a 17:28 - Costa Brava o Costa Daurada?
Jérôme Rothen se chauffe contre un autre consultant, un éditorialiste ou un acteur du foot.
Vi må unnskylde denne episoden av Genopodden! Vi vet at denne episoden vil gjøre deg sulten. Om vi skal kunne gi deg et godt tips før du skal lytte til denne episoden, må det være at du tar frem noen gode oster, sett deg godt til rette og bli med på denne lille ostereisen vi tok under Dyrsku`n!Dyrsku`n 2024 arrangerte ostevandringer sammen med Norsk Gardsost, Hanen og norske oseprodusenter. Rasmus Lang-Ree og Oda Christensen ble kyndig geleidet av Henry Mæland, som er veteran i Dyrsku-sammenheng. De fikk møte både produsenter, ei budeie, osteelskere og kokker.Visste du at vi har en egen osteløype i Norge? Et veikart hvor du kan sjekke opp osteprodusenter som selger ost direkte. Nytt for Genopodden var også at brunost kan brukes som sukkebit til kaffen. Og at gammelosten faktisk ikke er gammel, det er bare oppskriften som er gammel. En fantastisk tradisjonsost som Rasmus og Oda fikk skikkelig sansen for, og hvor innsalget inneholder både smak, bruksområder og proteininnholdet.At Genopodden er opptatt av mat bør ikke være en overraskelse. Alt henger sammen, og det skal være kvalitet i alle ledd for å lage en god ost. Barbro Stordalen, yster og budeie fra Stordalen Gard, er helt enig. - Om de ikke forstår at det skal være kvalitet i råstoffet for å lage ost, da kan jeg bli litt morsk, sier hun. Det var kun kvalitet Genopodden opplevde på denne ostereisen. Både når det gjelder kompetanse, oster og tilbehør. Heng på! La oss dykke ned i en liten flik av norske ostehistorie! Hosted on Acast. See acast.com/privacy for more information.
In this conversation with the Review of Democracy, Ho-fung Hung shares his eye-opening analysis of the internal contradictions and external limitations plaguing China's export-led development model and offers novel insights into the difficulties its political leadership is encountering in challenging US hegemony and extending its global sphere of influence. While acknowledging China's impressive achievements, Hung emphasizes China's technological dependency and chronic industrial overcapacity, the impact of the rise of protectionism, the hegemony of the US dollar, and China's lack of confidence in its military capabilities. At the same time, he forecasts the intensification of US-Chinese rivalry in connection with the gradual decoupling of the US and Chinese economies. Ho-fung Hung is Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Sociology Department of the Johns Hopkins University. His scholarly interests include global political economy, protest, nation-state formation, social theory, and East Asian Development. He is the author of the award-winning Protest with Chinese Characteristics (2011, Columbia UP), The China Boom: Why China Will not Rule the World (2016, Columbia UP) and the Clash of Empires: From “Chimerica” to the “New Cold War” (2022, Cambridge UP).
Esta mañana Carmen Lomana ha venido al programa para abrir su tribunal y juzgar dos nuevos casos: polémica en el photocall y Henry Méndez se enfrenta a un hombre en uno de sus conciertos. Además, descubrimos cómo fue la cita a ciegas entre Laura y Francisco y salimos a la calle para preguntarle a la gente qué podemos hacer para superar una ruptura amorosa. See omnystudio.com/listener for privacy information.
Esta mañana Carmen Lomana ha venido al programa para abrir su tribunal y juzgar dos nuevos casos: polémica en el photocall y Henry Méndez se enfrenta a un hombre en uno de sus conciertos. Además, descubrimos cómo fue la cita a ciegas entre Laura y Francisco y salimos a la calle para preguntarle a la gente qué podemos hacer para superar una ruptura amorosa. See omnystudio.com/listener for privacy information.
Esta mañana Carmen Lomana ha venido al programa para abrir su tribunal y juzgar dos nuevos casos: polémica en el photocall y Henry Méndez se enfrenta a un hombre en uno de sus conciertos. Además, descubrimos cómo fue la cita a ciegas entre Laura y Francisco y salimos a la calle para preguntarle a la gente qué podemos hacer para superar una ruptura amorosa. See omnystudio.com/listener for privacy information.
Henry Martyn Leland was an American machinist, inventor, engineer, and automotive entrepreneur. He founded the two premier American luxury automotive marques, Cadillac and Lincoln. His motto was, “Craftsmanship a creed, accuracy a law.” In this episode, we hear much about his determination and innovative genius from Karl Petry, a graduate of the Lincoln Technical Institute and admirer of Mr. Leland.
From the September/October 2016 edition of The Scottish Rite Journal. Any accompanying photographs or citations for this article can be found in the corresponding print edition.Make sure to like and subscribe to the channel! Freemasons, make sure you shout out your Lodge, Valley, Chapter or Shrine below!OES, Job's Daughter's, Rainbow, DeMolay? Drop us a comment too!To learn how to find a lodge near you, visit www.beafreemason.comTo learn more about the Scottish Rite, visit www.scottishrite.orgVisit our YouTube Page: Youtube.com/ScottishRiteMasonsVisit our new stores: Bookstore: https://www.srbookstore.myshopify.com/Merch Store: http://www.shopsrgifts.com/
What if the key to your personal growth was a heightened sense of awareness? Join us as we delve deep into the concept of the law of awareness, drawing inspiration from Philippians 3:14 and its powerful message on understanding our strengths, weaknesses and divine gifts. Dive into the gripping tale of Henry M., a man who lost his memory after surgery, a poignant allegory of our personal journey; his story underscores the importance of cognizance of our past, present, and future in self-improvement.With sage advice from JT Pew, we explore the application of the law of awareness to our everyday lives. By choosing the right paths, nurturing relationships, equipping ourselves with the right tools, adjusting our attitudes, and embracing leadership, we can drive personal growth. Furthermore, we reflect on the transformative power of a simple shift in attitude, and how it can radiate positivity to those around us. We conclude with an invitation to join our True North Nation community, and the significance of sharing and reviewing our podcast. Let's embark on this enlightening journey together, fostering growth and awareness one episode at a time.Support the showThank you for listening! If you don't mind, please leave us a review here on our website or your favorite listening platform. Also, please consider supporting us by becoming a Member of TNN. If you want to get some awesome coffee delivered to your door, check out fristcup.com/HealAmerica. Use our discount code TNN23 for an additional 10% off. Until next time, have a great day on purpose!Ed Snyder
Je suis ravie de vous retrouver pour la suite de l'interview de Victor Eremita. Dans le dernier épisode, mon invité nous a donné sa définition de la philosophie, une philosophie qui se veut connectée à l'existence, reliée à notre quotidien et aux sentiments qui nous traversent... dans l'idée d'apprendre, pas à pas, de se faire miroir fidèle du monde. Car il semble que nous aspirions tous, au fond, à cette Joie, à cet Amour inconditionnel. C'est ce "désir" fondamental, dont nous parlions la dernière fois. Selon Victor, pour cela, pas besoin d'une expérience mystique comme j'ai pu moi-même en vivre, de nombreux chemins permettent d'y arriver. Car comme il nous l'expliquait, je reprends ses termes, «Le réel est "un". Il n'y a pas deux réalités», «quand le miroir n'est plus déformant, on arrive au même résultat ». Donc aujourd'hui nous creusons l'idée que, grâce à la réflexion philosophique, nous puissions découvrir ce chemin qui mène à la Joie, et surtout que nous soyons capable de le retrouver et de le réemprunter. Loin des dogmes et des religions, nous parlerons donc, de Dieu, de Nature, de félicité. Et après il ne restera plus qu'à s'entrainer !
O fim do mundo é algo exclusivamente cristão ou mais culturas também já falavam ou ainda falam sobre isso? Separe trinta minutos do seu dia e aprenda com o professor Vítor Soares (@profvitorsoares) sobre o que foi a Ciência Nazista. - Se você quiser ter acesso a episódios exclusivos e quiser ajudar o História em Meia Hora a continuar de pé, clique no link: www.apoia.se/historiaemmeiahora - Compre nossas camisas, moletons e muito mais coisas com temática História na Lolja! www.lolja.com.br/creators/historia-em-meia-hora/ - PIX e contato: historiaemmeiahora@gmail.com Apresentação: Prof. Vítor Soares. Roteiro: Prof. Vítor Soares e Prof. Victor Alexandre (@profvictoralexandre) REFERÊNCIAS USADAS - Darmesteter, J. O Zend-Avesta. Clássicos Franklin, 2018. - Morris, Henry M (1985) [1983]. The Revelation Record. [S.l.]: Tyndale House and Creation Life - Collins, John J. (2010). The Apocalyptic Imagination: An Introduction to Jewish Apocalyptic Imagination 2ª ed. Wm. B. Eerdmans Publishing. - Karen Armstrong, Uma história de Deus. - Mitologia Nórdica. Neil Gaiman
Robert's Rules of Order Pocket Manual of Rules of Order for Deliberative Assemblies
Continuing in our Palm Beach Chronicles, this week we pick up the thread of Henry M. Flagler, big time deal in the town, and the tragic history of his three wives: Mary Harkness, Ida Alice Shourds, and Mary Lily Kenan.All sources can be found at doneanddone.com.Continue your investigation with ad-free and bonus episodes on Patreon!To advertise on Done & Dunne, please reach out to sales@advertisecast.com or visit https://www.advertisecast.com/DoneDunne. Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Continuing in our Palm Beach Chronicles, this week we pick up the thread of Henry M. Flagler, big time deal in the town, and the tragic history of his three wives: Mary Harkness, Ida Alice Shourds, and Mary Lily Kenan. All sources can be found at doneanddone.com. Continue your investigation with ad-free and bonus episodes on Patreon! To advertise on Done & Dunne, please reach out to sales@advertisecast.com or visit https://www.advertisecast.com/DoneDunne. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Identify "COVID Toes".Identify an unusual infection caused by Burkholderia.Know what to look for when 2 members of the same family present in the summer with fever and severe thrombocytopenia.
Content Warning: This episode contains brief depictions of cannibalism. This episode concludes the story of Henry M. Stanley. Listen to hear of his experiences exploring the Congo, being hunted by cannibals, and sharing the gospel with a Ugandan king. HMS BiographyWe're most active on TwitterPartner with Us:Join us on PatreonReach Out:Email us at revivedthoughts@gmail.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
This is Part 2 of the 3 Part adventures of Henry M. Stanley. Follow his journey to find Livingstone with the attached map. The MapHMS BiographyWe're most active on TwitterPartner with Us:Join us on PatreonReach Out:Email us at revivedthoughts@gmail.comFacebook GroupAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event, provides essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy. Upon completion of this activity, participants should be better able to: Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer, Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing, Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials, Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event, provides essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy. Upon completion of this activity, participants should be better able to: Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer, Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing, Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials, Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event, provides essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy. Upon completion of this activity, participants should be better able to: Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer, Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing, Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials, Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment.
Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.
"Doctor Livingstone I presume?" Everyone knows his famous line, but not many people know the man who uttered it. HMS BiographyWe're most active on TwitterPartner with Us:Join us on PatreonReach Out:Email us at revivedthoughts@gmail.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.
Listen to this recording of our discussion of "Robert's Rules of Order Newly Revised In Brief," a summarized version of the parliamentary rules most DSA chapters operate under.
As easily prevented as colorectal cancer is, Prostate Cancer remains second leading cause of death among men. Former LT Governor and Orthopedic Surgeon Stephen L. Henry, M.D. shares his personal journey with this highly treatable cancer when caught at an early stage.
Women with vaginas, respectfully, have more pressure to race their biological clock, but WHAT ABOUT THE PENIS OWNERS? On this episode, J.Mix sits down with Tony and Henry M. to explore the pressures they face with their biological c(l)ocks. ;) Topics discussed:Fear of being an "old dad," The meaning of life after age 30, Experiences desired before having kids, Financial stability, Having multiple kids because sibling love, Lack of compromising in relationships, Parenting outside of monogamy, and soooo much more!!! Click here for more info on Mental Health Awareness Month.Support J.Mix's work with this podcast and her performance career by joining TSAM's Patreon! www.patreon.com/theselfawaremillennial--Follow The Self-Aware Millennial on Instagram, and Youtube!--Inquiries? Compliments? Critiques? Contact theselfawaremillennial@gmail.com--Song(s): "The Self-Aware Millennial Theme" Version 3 + "Venturing" by J.Mix (Patreon Rap)--Resources:https://www.healthline.com/health/biological-clock-women#bottom-linehttps://www.phillymag.com/news/2020/02/01/millennials-having-kids/www.tsampodcast.comSupport the show (https://www.patreon.com/theselfawaremillennial)
In this episode, Professor Ho-Fung Hung describes his experience on the ground in Hong Kong from when he visited in August. Professor Hung also highlights the differences between old and new generations of protesters and looks ahead at what Hong Kong could look like in year 2047, when the “one country, two systems” arrangement is set to expire. Professor Ho-Fung Hung is the Henry M. and Elizabeth P. Wiesenfeld Professor in Political Economy at the Paul H. Nitze School of Advanced International Studies of the Johns Hopkins University.
Vidcast: https://youtu.be/P-1uQvW4Hew Studies of our gut's microbiome, our gastrointestinal tract's collection of bacteria, show that it has a huge role in our body's health. Most of our gut bacteria come from raw fruit and vegetables, since cooking kills the majority of those in other foods we eat. The most ubiquitous raw fruit is the apple, and it supplies many of the bacteria in our systems. An Austrian study of apples just published in the journal Frontiers of Microbiology shows that the most beneficial bacteria are found in apples grown organically. The highest numbers of bacteria are found in the seeds, the stems, and the ends of the apple, and those numbers are consistently higher for the organically-grown fruit. If you look closely at the data though, the organic advantage is not huge. Often the price difference is. The bottom line is eat apples, any apples, and get the best price so that you can buy more. Birgit Wassermann, Henry Müller, Gabriele Berg. An Apple a Day: Which Bacteria Do We Eat With Organic and Conventional Apples? Frontiers in Microbiology, 2019; 10 DOI: 10.3389/fmicb.2019.01629 #Apples, microbiome, organic
© 2020-2026 Ivy Podcast Discovery LLC
